Drug Trial Radar · NCT03535194
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
Last checked: Nov 20, 2026Latest source record: Mar 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,484
Actual
Start
Jun 26, 2018
Primary completion
Mar 5, 2020
Study completion Jun 3, 2020
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
MirikizumabDrug
Administered SC
PlaceboDrug
Administered SC
SecukinumabDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Static Physician's Global Assessment (sPGA) of (0,1) With at Least a 2-point Improvement From BaselineTime frame: Week 16
- Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From BaselineTime frame: Week 16
Locations
178 sites in 16 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California
David Stoll, M.D.
Beverly Hills, California
California Dermatology and Clinical Research Institute
Encinitas, California
Tien Q. Nguyen, MD inc. DBA First OC Dermatology
Fountain Valley, California
Keck School of Medicine University of Southern California
Los Angeles, California
Dermatology Clinical Trials
Newport Beach, California
San Luis Dermatology & Laser Clinic, Inc
San Luis Obispo, California
Clinical Science Institute
Santa Monica, California
Park Avenue Dermatology
Orange Park, Florida
Dermatologic Surgery Specialists, PC
Macon, Georgia
Medaphase Inc
Newnan, Georgia
Meridian Clinical Research
Savannah, Georgia
Treasure Valley Dermatology
Boise, Idaho
University Dermatology
Darien, Illinois
Arlington Dermatology
Rolling Meadows, Illinois
Dawes Fretzin Clinical Research
Indianapolis, Indiana
The Indiana Clinical Trials Center, PC
Plainfield, Indiana
The South Bend Clinic
South Bend, Indiana
Dermatology Specialist
Louisville, Kentucky
DelRicht Research
Baton Rouge, Louisiana
Dermatology and Skin Cancer Specialists
Rockville, Maryland
Lawrence J Green, M.D, LLC
Rockville, Maryland
ORA, Inc
Andover, Massachusetts
Central Dermatology PC
St Louis, Missouri
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Mount Sinai School of Medicine Dermatology Clinical Trials
New York, New York
PMG Research of Cary, LLC
Cary, North Carolina
University of North Carolina Dermatology and Skin Cancer Cen
Chapel Hill, North Carolina
PMG Research of Wilmington, LLC
Wilmington, North Carolina
Bexley Dermatology Research
Bexley, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Wright State Physicians Dermatology
Fairborn, Ohio
Oregon Dermatology and Research Center
Portland, Oregon
Oregon Health and Science University
Portland, Oregon
Clinical Partners LLC
Johnston, Rhode Island
Modern Research Associates PLLC
Dallas, Texas
Austin Institute for Clinical Research, Inc.
Pflugerville, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Jordan Valley Dermatology Center
West Jordan, Utah
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.